# Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis

> **NCT00594932** · PHASE1,PHASE2 · COMPLETED · sponsor: **Oklahoma Medical Research Foundation** · enrollment: 27 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Arthritis

## Interventions

- **DRUG:** mycophenolate mofetil
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00594932
- **Lead sponsor:** Oklahoma Medical Research Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-07
- **Final completion:** 2009-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2020-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00594932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00594932, "Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00594932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*